Φορτώνει......
The role of somatostatin in GLP-1-induced inhibition of glucagon secretion in mice
AIMS/HYPOTHESIS: Glucagon-like peptide-1 (GLP-1) receptor agonists are currently used for the treatment of type 2 diabetes. Their main mechanism of action is enhancement of glucose-induced insulin secretion (from increased beta cell glucose sensitivity) and inhibition of glucagon secretion. The latt...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Diabetologia |
|---|---|
| Κύριοι συγγραφείς: | , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Springer Berlin Heidelberg
2017
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5552842/ https://ncbi.nlm.nih.gov/pubmed/28551699 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00125-017-4315-2 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|